Cytodyn Inc (CYDY)

[HyGro]

LL NASH 350 mg was mediocre and is not competitive with the leading NASH competitors -- LL 16-20% vs. Madrigal 48% -- not even close. If 700 mg doubles the 350 (unlikely) it is still barely competitive. It is certainly NOT breakthrough. Who wants to partner with a mediocre drug candidate?? Nobody.

Cytodyn didn't even report fibrosis reduction data. Never a good sign when a company hides a secondary endpoint. Sorry never a good sign.

BP could buy Inventiva (a BTD drug) or Madrigal and get best in class NASH candidate that is much further along and much more certain of commercial viability. LL's NASH data is questionable as to whether it is worth spending the significant time and money for a Phase 3. Cytodyn isn't going to do it.